Clinical implications of CURE and PCI-CURE in patients with the acute coronary syndrome without persistent ST-elevation

Scandinavian Cardiovascular Journal

Volumn 36, Issue 5, 2002, Pages 261-271

  Otterstad, Jan Erik ^a   Fox, Keith A A ^b  

^a VESTFOLD HOSPITAL TRUST   (Norway)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; LANOFIBAN; LOW MOLECULAR WEIGHT HEPARIN; PHENYLBUTAZONE; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; GASTROINTESTINAL DISEASE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; ST SEGMENT ELEVATION; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANTICOAGULANTS; ASPIRIN; CORONARY DISEASE; ELECTROCARDIOGRAPHY; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SYNDROME; TICLOPIDINE;

EID: 0036433263     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/140174302320774447     Document Type: Article

References (33)

1. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinapyrizone, or both in unstable angina. Results of a Canadian multicenter trial. N Eng J Med 1985; 313: 1369-1375.
2. Wallentin LC and the Research Group on instability in coronary artery disease in Southeast Sweden. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. JACC 1991; 18: 1587-1593.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
4. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 811-815.
5. Fragmin during instability in coronary artery disease (FRISC) study group. Low-molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568.
6. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-452.
7. Kong DF, Califf RJ, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa Integrin in ischemic heart disease. Circulation 1998; 98: 2829-2835.
8. Boersma E, Harrington RA, Moliterno DJ. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-198.
9. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
10. Metha SR, Yusuf S, Peters RLG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-533.
11. Bertrand M, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes without persistent ST segment elevation. Task Force Report. Eur Heart J 2000; 21: 1406-1432.
12. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-1924.
13. Stables RH. Clopidogrel in invasive management of non-ST elevation ACS. Commentary. Lancet 2001; 358: 520-521.
14. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
15. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease. One year results of the ESSENCE study. JACC 2000; 36: 693-698.
16. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
17. Otterstad JE, Sleight P. The HOPE study: Comparison with other trials of secondary prevention. Clinical perspective. Eur Heart J 2001; 22: 1307-1310.
18. ISIS-2 collaborative group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; ii: 349-360.
19. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-1505.
20. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndrome. N Engl J Med 1998; 339: 436-443.
21. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoproteim IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998; 338: 1488-1497.
22. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998; 97: 2386-2395.
23. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429-1435.
24. The RESTORE Investigators. Effects of platelet glycoprotein IIB/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-1453.
25. The EPISTENT Investigators. Randomised placebo-controlled and balloon angioplasty - controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352: 87-92.
26. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
27. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.
28. The IMPACT Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997: 1422-1428.
29. Topol EJ, Moliterno DJ, Herrman HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors. Tirofibam and abciximab for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-1894.
30. Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701-707.
31. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-1887.
32. Antman EM, Cohen M, Bernik PJL, et al. The TIMI risk score for unstable angina/non-ST elevation MI. A method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-842.
33. The TIMI Study Group. Mueller HS, Forman SA, Menegus MA, Cohen LS, Knatterud GL, Braunwald E. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. N Engl J Med 1989; 320: 618-627.